Valuation : Tarsus Pharmaceuticals, Inc.

Market Cap 3.25B 2.8B 2.64B 2.4B 4.52B 309B 4.55B 31.25B 12.14B 157B 12.2B 11.93B 520B P/E 2026 *
-34.7x
P/E 2027 * 31.8x
Enterprise Value 3.25B 2.8B 2.64B 2.4B 4.52B 309B 4.55B 31.25B 12.14B 157B 12.2B 11.93B 520B EV / Sales 2026 *
4.55x
EV / Sales 2027 * 3.51x
Free-Float
97.13%
Yield 2026 *
-
Yield 2027 * -
1 day-0.26%
1 week+1.70%
Current month-0.26%
1 month+25.42%
3 months+24.66%
6 months-1.95%
Current year-9.56%
1 week 69.46
Extreme 69.465
75.08
1 month 57.63
Extreme 57.63
75.08
Current year 53.89
Extreme 53.89
83.92
1 year 48.2
Extreme 48.2
85.25
3 years 12.57
Extreme 12.57
85.25
5 years 10.8
Extreme 10.8001
85.25
10 years 10.8
Extreme 10.8001
85.25
Manager TitleAgeSince
Chief Executive Officer 48 2018-08-31
Director of Finance/CFO 64 2023-04-23
Chief Tech/Sci/R&D Officer 47 2024-11-03
Director TitleAgeSince
Chairman 48 2022-12-01
Director/Board Member 71 2019-11-30
Director/Board Member 80 2016-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
4/24/26 Exercice

Director

2,766 0.0065%
3/20/26 Sell

Chief Operating Officer

2,989 0.0070%
3/17/26 Sell

Head of Human Resources

12,274 0.0288%
Change 5-day change 1-year change 3-year change Capi.($)
-0.26%+1.70%+26.41%+322.90% 3.26B
+3.10%-0.56%+41.87%-0.32% 79.79B
+0.43%+1.89%-19.06%-37.01% 58.85B
+9.93%+11.07%+540.39%+36.44% 56.03B
+0.13%-3.37%-1.24%+34.14% 51.26B
+1.49%-0.68%+9.33%+163.89% 47.68B
-0.28%-0.95%+63.39%-19.20% 32.01B
+1.45%-2.32%+47.75%+93.72% 24.98B
-2.12%+2.11%+4.90%+189.46% 23.05B
+1.69%+1.19%+59.26%+116.16% 16.31B
Average +0.39%-0.69%+77.30%+90.02% 39.32B
Weighted average by Cap. +0.66%-1.48%+94.77%+46.90%

Financials

2026 *2027 *
Net sales 714M 616M 579M 528M 992M 67.75B 999M 6.86B 2.67B 34.44B 2.68B 2.62B 114B 925M 798M 751M 685M 1.29B 87.85B 1.29B 8.9B 3.46B 44.66B 3.47B 3.4B 148B
Net income -95.74M -82.59M -77.71M -70.84M -133M -9.09B -134M -921M -358M -4.62B -359M -352M -15.33B 116M 99.99M 94.09M 85.77M 161M 11.01B 162M 1.11B 433M 5.59B 435M 426M 18.57B
Net Debt - -
Logo Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company's lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. It is investigating the development of its product candidates to address targeted diseases with medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction. It is also developing IRX-101, an investigational ocular antiseptic.
Employees
370
Date Price Change Volume
26-09-01 $74.05 -0.26% 587,079
26-08-31 $74.24 +3.46% 711,972
26-08-28 $71.76 -0.22% 615,743
26-08-27 $71.92 +1.80% 876,933
26-08-26 $70.65 -1.12% 611,550
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
74.05USD
Average target price
94.86USD
Spread / Average Target
+28.10%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TARS Stock